Tag: David J. Bearss
Tolero, AbbVie to explore venetoclax alvocidib combo for AML
Tolero Pharmaceuticals said that its cyclin-dependent kinase 9 (CDK9) inhibitor alvocidib will be combined with AbbVie leukemia drug venetoclax to evaluate their potential in their ... Read More